• Home
  • Search Results
  • Combination dihydroergotamine mesylate and heparin sodium with lidocaine HCl. Pharmacokinetics, mechanism of action, clinical efficacy, and adverse effects.

Combination dihydroergotamine mesylate and heparin sodium with lidocaine HCl. Pharmacokinetics, mechanism of action, clinical efficacy, and adverse effects.

Pharmacotherapy (1986-07-01)
J A Barone, J J Raia, D B Levy
ABSTRACT

Dihydroergotamine(DHE)-heparin combination offers a unique treatment modality for the prevention of deep vein thrombosis. The combination appears to affect all 3 limbs of Virchow's triad: hypercoagulability, venous stasis, and endothelial damage. In most efficacy studies, data indicated that the combination of DHE 0.5 mg and heparin 5000 IU was superior to low-dose heparin alone. Even when the efficacy of DHE-heparin was the same as that of heparin alone, the use of the combination allowed for a decrease in the heparin dose required.

MATERIALS
Product Number
Brand
Product Description

USP
Dihydroergotamine mesylate, United States Pharmacopeia (USP) Reference Standard
Dihydroergotamine for peak identification, European Pharmacopoeia (EP) Reference Standard
Dihydroergotamine mesilate, European Pharmacopoeia (EP) Reference Standard